Novo Nordisk ADR [NYSE: NVO] stock went on a downward path that fall over -2.84% on Thursday, amounting to a one-week price decrease of less than -1.64%.
Over the last 12 months, NVO stock rose by 57.55%. The one-year Novo Nordisk ADR stock forecast points to a potential upside of 12.47. The average equity rating for NVO stock is currently 1.94, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $426.85 billion, with 3.38 billion shares outstanding and 3.34 billion shares in the current float. Compared to the average trading volume of 3.91M shares, NVO stock reached a trading volume of 5301852 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Novo Nordisk ADR [NVO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVO shares is $146.08 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVO stock is a recommendation set at 1.94. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Novo Nordisk ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 30, 2024. While these analysts kept the previous recommendation, BMO Capital Markets raised their target price to Outperform. The new note on the price target was released on April 12, 2024, representing the official price target for Novo Nordisk ADR stock. Previously, the target price had yet another raise to $120, while Morgan Stanley analysts kept a Overweight rating on NVO stock.
The Average True Range (ATR) for Novo Nordisk ADR is set at 3.49, with the Price to Sales ratio for NVO stock in the period of the last 12 months amounting to 12.02. The Price to Book ratio for the last quarter was 39.80, with the Price to Cash per share for the same quarter was set at 0.40. Price to Free Cash Flow for NVO in the course of the last twelve months was 45.96 with Quick ratio for the last quarter at 0.50.
NVO Stock Performance Analysis:
Novo Nordisk ADR [NVO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.64. With this latest performance, NVO shares dropped by -12.97% in over the last four-week period, additionally plugging by 21.53% over the last 6 months – not to mention a rise of 57.55% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVO stock in for the last two-week period is set at 33.57, with the RSI for the last a single of trading hit 27.84, and the three-weeks RSI is set at 38.12 for Novo Nordisk ADR [NVO]. The present Moving Average for the last 50 days of trading for this stock 138.47, while it was recorded at 131.49 for the last single week of trading, and 119.36 for the last 200 days.
Insight into Novo Nordisk ADR Fundamentals:
Novo Nordisk ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.50 and a Current Ratio set at 0.70.
NVO Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novo Nordisk ADR go to 2.80%.
Novo Nordisk ADR [NVO] Institutonal Ownership Details
The top three institutional holders of NVO stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.5034%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $178.43 billion in NVO stocks shares; and BERKSHIRE HATHAWAY INC, currently with $135.36 billion in NVO stock with ownership which is approximately 5.1238%.
